aim
studi
estim
incid
gastrointestin
stromal
tumor
previou
diagnos
confirm
andor
revis
immunohistochem
mutat
analys
review
surgic
excis
gastrointestin
lesion
hospit
mesenchym
tumor
examin
express
immunohistochemistri
everi
mesenchym
tumor
subject
mutat
analysi
kit
pdgfra
exon
result
show
approxim
gastrointestin
stromal
tumor
misdiagnos
immunohistochem
analysi
express
perform
approxim
misdiagnos
mutat
analysi
avail
approxim
patient
gastrointestin
malign
taiwan
treat
hospit
averag
newli
diagnos
gastrointestin
stromal
tumor
hospit
case
per
introduct
term
gastrointestin
gi
stromal
tumor
gist
two
decad
earlier
tumor
kind
often
diagnos
smoothmuscl
tumor
afterward
gist
either
use
inclus
term
refer
mesenchym
tumor
regardless
differenti
phenotyp
exclus
term
mesenchym
tumor
differenti
schwann
cell
smoothmuscl
cell
terminolog
flux
exampl
gastrointestin
autonom
nerv
tumor
known
plexosarcoma
use
tumor
kind
show
ultrastructur
featur
complex
interdigit
cell
process
neurosecretori
granul
intermedi
filament
estim
incid
gist
sens
heterogen
neoplasm
approxim
per
million
express
gist
propos
import
piec
evid
link
histogenesi
gist
interstiti
cell
cajal
pacemak
cell
autonom
gut
motil
sinc
diagnosi
gist
becom
specif
requir
inclus
immunoposit
perspect
incid
gist
approxim
per
million
recent
studi
shown
gainoffunct
mutat
kit
initi
oncogen
step
lead
tabl
analysi
surgic
excis
gastrointestin
lesion
categori
year
esophagu
stomach
small
intestin
appendix
colorectum
total
nonneoplast
neoplast
epitheli
carcinoma
mesenchym
develop
gist
sever
investig
show
gist
harbor
kit
mutat
approxim
gist
lack
mutat
kit
pdgfra
mutat
discoveri
mutat
gene
gist
import
therapeut
point
view
gist
harbor
mutat
respond
imatinib
mesyl
glivec
novarti
pharma
basel
switzerland
addit
therapeut
implic
mutat
analysi
provid
addit
diagnost
indic
gist
immunoneg
gist
like
overlook
unless
mutat
kit
pdgfra
gene
identifi
tumor
regard
incid
gist
includ
one
remain
estim
data
import
healthcar
provid
regard
avail
imatinib
mesyl
remark
effect
expens
therapeut
agent
gist
studi
aim
determin
incid
gist
specif
morpholog
context
posit
express
immunohistochemistri
ihc
andor
presenc
kit
pdgfra
mutat
center
northern
taiwan
patholog
archiv
surgic
excis
specimen
exclud
endoscop
biopsi
gi
tract
review
studi
conduct
accord
guidelin
institut
review
board
mmh
hematoxylin
eosinstain
along
immunostain
section
mesenchym
lesion
gi
tract
retriev
gastrointestin
cancer
treat
mmh
identifi
use
intern
classif
diseas
system
code
follow
code
esophag
carcinoma
code
gastric
adenocarcinoma
code
adenocarcinoma
small
intestin
code
colorect
carcinoma
ihc
express
perform
mesenchym
tumor
gi
tract
brief
repres
section
specimen
deparaffin
xylen
rehydr
seri
grade
alcohol
react
antibodi
dilut
dako
carpinteria
ca
immunoreact
detect
accord
manufactur
instruct
ventana
medic
systen
tucson
az
diaminobendizin
contain
hydrogen
peroxid
employ
chromogen
posit
immunostain
defin
tumor
cell
strongli
immunoreact
tumor
dna
isol
formalinfix
paraffinembed
tumor
subject
pcr
amplif
use
eight
pair
oligonucleotid
primer
exon
kit
exon
pdgfra
accord
previous
describ
procedur
result
amplicon
sequenc
use
abi
prism
bigdy
termin
cycl
sequenc
readi
reaction
kit
abi
prism
genet
analyz
pe
appli
biosystem
foster
citi
ca
surgic
excis
specimen
gi
tract
hospit
tabl
among
n
nonneoplast
lesion
n
epitheli
tumor
n
mesenchym
tumor
latter
includ
gist
gist
nongist
mesenchym
tumor
subtot
review
past
diagnos
made
immunohistochem
analysi
express
routin
use
hospit
mesenchym
tumor
gi
tract
found
five
case
gist
misdiagnos
two
case
therefor
misdiagnosi
rate
morpholog
assess
without
ancillari
ihc
express
approxim
tabl
everi
mesenchym
lesion
gi
tract
morpholog
indistinguish
gist
genom
kit
exon
pdgfra
exon
sequenc
specif
morpholog
context
kit
pdgfra
mutant
tumor
classifi
gist
regardless
ihc
result
base
approach
two
case
gist
three
case
misdiagnos
indic
approxim
misdiagnosi
rate
ancillari
mutat
analysi
avail
tabl
among
gist
stomach
common
site
tumor
involv
follow
small
intestin
tabl
approxim
n
gist
incident
identifi
surgeri
adenocarcinoma
eight
tumor
lymphoma
one
tumor
shown
fig
gist
patient
per
year
sinc
hospit
becom
referr
center
gist
patient
thu
annual
case
number
dramat
increas
thereaft
except
emerg
epidem
corona
viru
infect
sever
acut
respiratori
syndrom
sar
caus
nearli
complet
shutdown
hospit
approxim
month
therefor
subsequ
analysi
incid
gist
base
data
obtain
estim
percentag
gi
cancer
patient
taiwan
treat
hospit
period
analyz
patient
code
hospit
regist
nationwid
databas
depart
health
execut
yuan
taiwan
accord
public
databas
case
gastrointestin
cancer
case
case
tabl
incid
esophag
cancer
surgic
treat
hospit
account
incid
diseas
diagnos
taiwan
along
line
ratio
gastric
small
intestin
incid
gist
known
underestim
definit
evolv
last
decad
diagnost
criteria
modifi
accordingli
includ
immunohistochem
analysi
express
well
mutat
analysi
kit
pdgfra
diagnosi
gist
calcul
annual
incid
gist
taiwan
per
million
estim
incid
much
higher
recent
studi
unit
state
base
data
nation
cancer
institut
surveil
epidemiolog
endresult
seer
registri
report
incid
rate
per
million
specul
incid
may
overestim
possibl
inclus
nongist
tumor
calcul
base
find
gist
would
misdiagnos
mesenchym
tumor
immunohistochem
molecular
analys
employ
diagnosi
believ
seer
rate
fact
underestim
howev
address
seer
data
includ
gist
diagnos
benign
tumor
therefor
seer
rate
probabl
reflect
incid
gist
high
intermedi
risk
malign
estim
incid
per
million
higher
iceland
annual
incid
per
million
report
differ
two
rate
could
explain
inclus
gist
racial
factor
ignor
incid
gist
taiwan
slightli
lower
sweden
annual
incid
per
million
report
true
annual
incid
gist
sweden
would
probabl
higher
gist
includ
slight
differ
annual
incid
taiwan
sweden
could
explain
least
part
autopsi
case
none
gist
analyz
studi
identifi
autopsi
case
wherea
gist
sweden
studi
incident
identifi
time
autopsi
addit
differ
could
also
explain
racial
variat
seer
studi
point
signific
differ
incid
asian
pacif
island
per
million
white
per
million
regard
popul
taiwan
compris
predominantli
han
chines
small
portion
indigen
peopl
consist
nine
aborigin
tribe
undetermin
origin
limit
studi
need
mention
specimen
analyz
studi
surgic
excis
tumor
symptomat
treatment
incid
report
interpret
context
therefor
rate
theoret
lower
japan
gist
like
diagnos
remov
endoscop
biopsi
countri
conclus
base
immunohistochem
molecular
analys
report
incid
gist
taiwanes
approxim
per
million
similar
scandinavia
studi
also
indic
caution
exercis
report
incid
gist
interpret
rate
may
decreas
ancillari
diagnost
test
use
increas
incident
identifi
case
autopsi
small
biopsi
includ
true
incid
gist
may
final
determin
accur
rate
report
variou
ethnic
group
racial
factor
clarifi
